Ron Najafi, chairman and CEO of NovaBay, said: “We are very pleased to have received rapid clearance of this important investigational new drug application (IND), as this enables us to stay on track with our clinical development programs and targeted milestones. Our current plans are to move NVC-422 into clinical trials for additional indications during 2008 through both our internal programs and those of our partner, Alcon.”